Today: 22 March 2026
Subscribe
Browse Category

Financial Forecasts 20 December 2025

IBM Stock News and Forecast for 2026: IBM Shares Hold Near $301 as Confluent Deal, Credit Outlook, and Analyst Calls Collide (Dec. 20, 2025)

IBM Stock News and Forecast for 2026: IBM Shares Hold Near $301 as Confluent Deal, Credit Outlook, and Analyst Calls Collide (Dec. 20, 2025)

IBM closed at $300.98 on Dec. 19, 2025, near the top of its 52-week range. The company announced an $11 billion deal to acquire Confluent, drawing scrutiny after S&P Global revised IBM’s outlook to negative over leverage concerns. The EU imposed new regulatory oversight, and analysts issued a downgrade on Dec. 20.
20 December 2025
···
Insmed (INSM) Stock News and Forecasts on Dec. 20, 2025: Brinsupri Trial Miss, Truist Upgrade, and Updated Price Targets

Insmed (INSM) Stock News and Forecasts on Dec. 20, 2025: Brinsupri Trial Miss, Truist Upgrade, and Updated Price Targets

Insmed shares closed at $174.84 Friday, rebounding 5% after a sharp drop triggered by its Phase 2b BiRCh trial failure in chronic rhinosinusitis without nasal polyps. The company discontinued development for that indication and announced the acquisition of a Phase 2–ready monoclonal antibody, INS1148, to expand its pipeline.
20 December 2025
··
Texas Instruments Stock (NASDAQ: TXN) on Dec. 20, 2025: Sherman Fab Starts Production, Analysts Split on the 2026 Outlook

Texas Instruments Stock (NASDAQ: TXN) on Dec. 20, 2025: Sherman Fab Starts Production, Analysts Split on the 2026 Outlook

Texas Instruments began production at its new Sherman, Texas 300mm wafer fab, part of a planned $40 billion investment. Shares closed at $176.29 on Dec. 19, as investors weighed long-term manufacturing gains against short-term margin concerns. Goldman Sachs downgraded the stock to Sell, citing risks from increased capacity and potential earnings drag.
20 December 2025
··
Salesforce (CRM) Stock News and Forecasts on Dec. 20, 2025: Agentforce AI Momentum, Qualified Acquisition, and Wall Street Price Targets

Salesforce (CRM) Stock News and Forecasts on Dec. 20, 2025: Agentforce AI Momentum, Qualified Acquisition, and Wall Street Price Targets

Salesforce shares closed at $259.91 on Dec. 19, up 0.8%, with about 20.7 million shares traded. The stock remains far below its 52-week high, as investors weigh AI growth prospects against weak SaaS sentiment. Q3 FY2026 revenue rose 9% to $10.3 billion, with Agentforce + Data 360 annual recurring revenue up 114% to $1.4 billion. Salesforce raised its full-year revenue outlook to $41.45–$41.55 billion.
20 December 2025
···
CoreWeave (CRWV) Stock News and Forecasts for Dec. 20, 2025: DOE “Genesis Mission” Boosts Shares as Analysts Debate AI Data-Center Risks

CoreWeave (CRWV) Stock News and Forecasts for Dec. 20, 2025: DOE “Genesis Mission” Boosts Shares as Analysts Debate AI Data-Center Risks

CoreWeave shares jumped 22% to $83 at Friday’s close, partially rebounding from a recent selloff. The move followed news that the company was named as a participant in the U.S. Department of Energy’s Genesis Mission and Citigroup resumed coverage with a Buy rating but lowered its price target.
20 December 2025
··
Lamb Weston (LW) Stock Plunges After Earnings Beat: Margin Pressure, 2026 Outlook, and Analyst Forecasts as of Dec. 20, 2025

Lamb Weston (LW) Stock Plunges After Earnings Beat: Margin Pressure, 2026 Outlook, and Analyst Forecasts as of Dec. 20, 2025

Lamb Weston shares plunged nearly 26% Friday after management warned of continued discounting and higher international costs despite beating Q2 FY2026 earnings expectations. Net sales rose 1% to $1.618 billion, with an 8% volume gain offset by an 8% drop in price/mix. The company said margin pressure may persist into the second half of the year.
20 December 2025
···
Disc Medicine (NASDAQ: IRON) Stock Drops on FDA Voucher Speculation: Latest News, Analyst Forecasts, and What Investors Watch Next

Disc Medicine (NASDAQ: IRON) Stock Drops on FDA Voucher Speculation: Latest News, Analyst Forecasts, and What Investors Watch Next

Disc Medicine (NASDAQ: IRON) shares fell 11.5% to $80.04 on Dec. 20, 2025, after a STAT News report raised doubts about the effectiveness of its lead drug bitopertin and the FDA’s fast-track voucher process. The stock traded between $71.46 and $94.60 on heavy volume after Truist Securities cited the report, fueling concerns about the viability of accelerated approval.
20 December 2025
·
Eli Lilly (LLY) Stock Outlook on Dec. 20, 2025: Orforglipron Pill Data, Price Cuts, and 2026 Forecasts Put the $1 Trillion Drugmaker Back in Focus

Eli Lilly (LLY) Stock Outlook on Dec. 20, 2025: Orforglipron Pill Data, Price Cuts, and 2026 Forecasts Put the $1 Trillion Drugmaker Back in Focus

Eli Lilly shares closed at $1,071.44 on Dec. 19, near record highs, after reporting positive Phase 3 results for its oral weight-loss drug orforglipron. The company also cut prices on Zepbound and Mounjaro in the U.S. and Canada. Lilly’s market value surpassed $1 trillion this year amid growing demand for obesity and cardiometabolic treatments.
20 December 2025
···
BioMarin (BMRN) Stock Surges on $4.8B Amicus Deal: Latest News, Analyst Forecasts, and What to Watch Next (Dec. 20, 2025)

BioMarin (BMRN) Stock Surges on $4.8B Amicus Deal: Latest News, Analyst Forecasts, and What to Watch Next (Dec. 20, 2025)

BioMarin shares jumped 17.7% to $61.15 Friday after announcing a $4.8 billion all-cash deal to acquire Amicus Therapeutics at $14.50 per share. The acquisition adds two marketed rare-disease drugs and a Phase 3 asset, and resolves U.S. patent litigation over Galafold, delaying generic entry to 2037. BioMarin expects the deal to close in Q2 2026 and be accretive to earnings within a year.
20 December 2025
····
Cisco (CSCO) Stock News, Analyst Forecasts, and 2026 Outlook: What Investors Are Watching on Dec. 20, 2025

Cisco (CSCO) Stock News, Analyst Forecasts, and 2026 Outlook: What Investors Are Watching on Dec. 20, 2025

Cisco shares closed Friday at $78.42, up 1.91%, after heavy trading pushed the stock near its all-time high set during the dot-com era. Morgan Stanley raised its price target to $91 on Dec. 17, citing AI infrastructure demand. Jackson Square Capital increased its stake in Cisco during the third quarter. The company faces scrutiny over a newly disclosed high-severity cybersecurity issue.
20 December 2025
··
CoreWeave Stock (CRWV) Surges on DOE Genesis Mission and Citi Buy Call: News, Forecasts, and 2026 Risks (Dec. 20, 2025)

CoreWeave Stock (CRWV) Surges on DOE Genesis Mission and Citi Buy Call: News, Forecasts, and 2026 Risks (Dec. 20, 2025)

CoreWeave shares surged 22.5% to about $83 in heavy trading after Citigroup resumed coverage with a Buy rating and the U.S. Department of Energy named the company as a Genesis Mission partner. Citi lowered its price target to $135 and flagged “High Risk,” citing strong demand but operational challenges. The stock had dropped 65% from its June high after its March IPO.
20 December 2025
···
National Stock Exchange of India (NSE) Today: Derivatives Reforms, IPO Signals, and Nifty 50 Forecasts as 2026 Approaches

National Stock Exchange of India (NSE) Today: Derivatives Reforms, IPO Signals, and Nifty 50 Forecasts as 2026 Approaches

The National Stock Exchange of India introduced a pre-open session for equity derivatives, aiming to set opening prices through a call auction. On December 20, the Nifty 50 closed at 25,966.40, up 0.58%. The exchange’s listed market capitalization stood at about $5.2 trillion. The long-delayed NSE IPO remains under discussion amid regulatory changes.
20 December 2025
·
Recursion Pharmaceuticals Stock (RXRX) News and Forecasts for Dec. 20, 2025: TUPELO Trial Data, JPMorgan Upgrade, and What Comes Next

Recursion Pharmaceuticals Stock (RXRX) News and Forecasts for Dec. 20, 2025: TUPELO Trial Data, JPMorgan Upgrade, and What Comes Next

Recursion Pharmaceuticals shares surged 11% on Dec. 17 after JPMorgan upgraded the stock, then retreated to close at $4.26 on Dec. 19 as trading volume spiked. The moves followed positive Phase 1b/2 data for REC-4881 in familial adenomatous polyposis, showing a median 43% reduction in polyp burden at 13 weeks. Most adverse events were mild or moderate.
20 December 2025
···
Trump Media (DJT) Stock Jumps After $6 Billion Fusion Merger Plan: Latest News, Forecasts, and What Investors Are Watching (Dec. 20, 2025)

Trump Media (DJT) Stock Jumps After $6 Billion Fusion Merger Plan: Latest News, Forecasts, and What Investors Are Watching (Dec. 20, 2025)

Trump Media & Technology Group and TAE Technologies announced a $6 billion all-stock merger on Dec. 18, aiming to build a utility-scale fusion power plant by 2026. DJT shares surged 42% on Dec. 18 and another 8% on Dec. 19, closing at $16.09 on heavy volume. Ownership of the combined company is expected to split roughly 50/50, with Trump Media committing up to $300 million in cash support.
20 December 2025
···
Ferrovial SE Stock (NASDAQ: FER) News and Forecasts for Dec. 20, 2025: Nasdaq-100 Entry, €800M Buyback, Dividend, and the 2026 Outlook

Ferrovial SE Stock (NASDAQ: FER) News and Forecasts for Dec. 20, 2025: Nasdaq-100 Entry, €800M Buyback, Dividend, and the 2026 Outlook

Ferrovial will join the Nasdaq-100 on December 22, becoming the first IBEX 35-listed company in the index. The move follows the launch of an €800 million share buyback and a €0.077 per share cash dividend, both set for December. U.S. shares closed at $66.39 on December 19, with trading volume spiking to 61.8 million that day.
20 December 2025
··
NVIDIA Corporation Stock (NVDA) News Today: China H200 Export Review, Intel Investment Cleared, and Fresh 2026 Price Targets

NVIDIA Corporation Stock (NVDA) News Today: China H200 Export Review, Intel Investment Cleared, and Fresh 2026 Price Targets

Nvidia shares rose nearly 4% to $180.99 after news that a U.S. interagency review could allow H200 AI chip sales to China under a licensing framework. The Commerce Department has sent license applications to State, Energy, and Defense for review, with a final decision possible from President Trump if agencies disagree. China remains a key market, but regulatory and geopolitical hurdles persist.
20 December 2025
·
HYMC Stock News and Forecast: Hycroft Mining’s Silver Drill Results, Insider Buying, and 2026 Catalysts as of Dec. 20, 2025

HYMC Stock News and Forecast: Hycroft Mining’s Silver Drill Results, Insider Buying, and 2026 Catalysts as of Dec. 20, 2025

Hycroft Mining shares traded around $16.42 on Dec. 20 after a volatile session, with volume near 4.8 million shares. The stock surged following a Dec. 15 update reporting the highest silver grades yet at its Nevada Vortex target, including a 30.8-meter intercept at 438.58 g/t silver. Drilling continues at both Vortex and Brimstone.
20 December 2025
···
Firefly Aerospace Stock (NASDAQ: FLY) News, Forecasts, and Analysis for Dec. 20, 2025

Firefly Aerospace Stock (NASDAQ: FLY) News, Forecasts, and Analysis for Dec. 20, 2025

Firefly Aerospace shares surged 22.82% Friday to $24.65, with after-hours trading near $25.44. The move followed new analyst coverage from KeyBanc and the appointment of Ramon Sanchez as COO, focused on scaling production. The stock has traded between $16 and $73.80 over the past year. Investors remain focused on execution risks and upcoming lunar-mission partnerships.
20 December 2025
···
Lamb Weston Stock (NYSE: LW) Sinks After Earnings: Discounting, Margin Pressure, Dividend Hike, and Fresh 2026 Forecasts (20 Dec 2025)

Lamb Weston Stock (NYSE: LW) Sinks After Earnings: Discounting, Margin Pressure, Dividend Hike, and Fresh 2026 Forecasts (20 Dec 2025)

Lamb Weston shares fell about 20% on December 19 after the company reported fiscal Q2 2026 results that beat expectations but maintained a cautious full-year outlook. The stock closed near $43.94 on December 20. Despite 8% volume growth, price/mix dropped 8%, pressuring margins. Investors focused on the company’s reliance on discounting and muted demand signals.
20 December 2025
···
1 … 9 10 11 12 13 … 42

Stock Market Today

  • Orla Mining Falls 14% After Camino Rojo Expansion Approval and 2026 Outlook Update
    March 22, 2026, 2:59 AM EDT. Orla Mining (TSX:OLA) shares fell 14.2% following its release of audited 2025 results and updated 2026 production guidance. The company reported 95,405 ounces of gold produced in Q4 and 300,620 ounces for the full year, with sales hitting US$1.06 billion. A key development was full environmental approval for an expanded open-pit and underground exploration at the Camino Rojo mine in Mexico, reducing regulatory risks and enabling a revised mine plan. While the approval supports near-term production growth, investors face execution risks related to costs and geotechnical factors. Forecasts include $1.4 billion revenue and $722 million earnings by 2028, implying substantial growth. Optimistic analysts expect faster expansion, though consensus remains cautious. The stock's fair value estimates range between CA$28.22 and CA$31.86, indicating upside potential amid execution uncertainties.
Go toTop